After ASTH’s 33% Climb in a Month, NUTX Looks Like the Stronger Long-Term Play
Nutex Health (NUTX) offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Astrana Health (ASTH), suggesting you may be better off investing in NUTX
- NUTX’s quarterly revenue growth was 214.0%, vs. ASTH’s 34.7%.
- In addition, its Last 12 Months revenue growth came in at 141.3%, ahead of ASTH’s 52.0%.
- NUTX’s LTM margin is higher: 33.4% vs. ASTH’s 2.9%.
ASTH provides technology-driven medical care through a network of primary, specialist, and hospitalist physicians, serving patients covered by private and public insurance programs. NUTX operates hospital and population health divisions, managing 21 facilities across 8 states with micro-hospitals, specialty hospitals, and outpatient departments.
Valuation & Performance Overview
| ASTH | NUTX | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 21.9 | 2.4 | NUTX |
| Revenue Growth | |||
| Last Quarter | 34.7% | 214.0% | NUTX |
| Last 12 Months | 52.0% | 141.3% | NUTX |
| Last 3 Year Average | 36.8% | 44.6% | NUTX |
| Operating Margins | |||
| Last 12 Months | 2.9% | 33.4% | NUTX |
| Last 3 Year Average | 5.8% | 5.2% | ASTH |
| Momentum | |||
| Last 3 Year Return | -27.8% | -78.7% | ASTH |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: ASTH Revenue Comparison | NUTX Revenue Comparison
See more margin details: ASTH Operating Income Comparison | NUTX Operating Income Comparison
But do these numbers tell the full story? Read Buy or Sell NUTX Stock to see if Nutex Health’s edge holds up under the hood or if Astrana Health still has cards to play (see Buy or Sell ASTH Stock).
That is one way to look at stocks. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure
Historical Market Performance
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| ASTH Return | -1% | 302% | -60% | 29% | -18% | -1% | 67% | ||
| NUTX Return | -30% | 0% | 35% | -91% | 17% | 183% | -69% | ||
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 10% | 100% | <=== | |
| Monthly Win Rates [3] | |||||||||
| ASTH Win Rate | 50% | 75% | 42% | 58% | 33% | 57% | 53% | ||
| NUTX Win Rate | 8% | 0% | 42% | 17% | 50% | 57% | 29% | ||
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 57% | 62% | <=== | |
| Max Drawdowns [4] | |||||||||
| ASTH Max Drawdown | -48% | 0% | -63% | -6% | -18% | -32% | -28% | ||
| NUTX Max Drawdown | -43% | 0% | -61% | -91% | -84% | -3% | -47% | ||
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | -12% | <=== | |
[1] Cumulative total returns since the beginning of 2020
[2] 2025 data is for the year up to 8/27/2025 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read NUTX Dip Buyer Analyses and ASTH Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.